Disclosed herein are compounds, compositions, methods and formulations therefor, for preventing and treating proliferative diseases associated with aberrant receptor tyrosine kinase (RTK) activity. The therapeutic formulations described herein more specifically relate to the non-selective inhibition of RTKs associated with vascular and pulmonary disorders.